UVI5008: the first reversible, non-covalent Bruton's tyrosine kinase epi-inhibitor for B-cell malignancies.

J Hematol Oncol · 2026 · PMC13032278 · PMID 41724980

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Mice treated with UVI5008 at 20 mg/kg displayed a decreasing trend in the number of leukemic cells in lymphoid tissues compared to control vehicle-treated mice.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.